| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, General Counsel
2 companies
Lee Chan Henry serves as a SVP, General Counsel at BEIGF and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 0 buys and 45 sells.
Historically, Lee Chan Henry's trades have earned a below-average insider score of 49/100 across 21 rated trades. Over a 12-month horizon, 20.0% of those trades were profitable, with an average 12-month return of -25.6%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 6, 2025 | ONC Beone Medicines Ltd. | SVP, General Counsel | Sell | 700 | $256.11 | $179,279.88 | -100% | +24.6% | - | |
| Feb 27, 2025 | ONC Beone Medicines Ltd. | SVP, General Counsel | Sell10b5-1 | 1,205 | $275.00 | $331,375.00 | -100% | -13.6% | +13.8% | |
| Feb 21, 2025 | ONC Beone Medicines Ltd. | SVP, General Counsel | Sell10b5-1 | 1,202 | $258.04 | $310,169.72 | -100% | -6.5% | +41.8% | |
| Sep 30, 2024 | ONC Beone Medicines Ltd. | SVP, General Counsel | Sell10b5-1 | 1,202 | $237.10 | $284,994.20 | -100% | -18.1% | +51.8% | |
| Jul 30, 2024 | ONC Beone Medicines Ltd. | SVP, General Counsel | Sell | 834 | $160.57 | $133,915.38 | -100% | +38.4% | +91.1% | |
| Jun 17, 2024 | ONC Beone Medicines Ltd. | SVP, General Counsel | Sell | 439 | $159.35 | $69,955.02 | -100% | +23.3% | +59.4% | |
| Jul 31, 2023 | ONC Beone Medicines Ltd. | SVP, General Counsel | Sell | 791 | $216.26 | $171,059.05 | -100% | -12.9% | -26.7% |